Plasma hsa-mir-19b is a potential LevoDopa therapy marker
| Autor: | Ruxandra Julia Vorovenci, Mihaela Simu, Cristina Bejinar, Inge Krabbendam, Amalia M. Dolga, Ioan Ovidiu Sirbu, Cristina Dijmarescu, Cecilia Rosca, Aimee Rodica Chis, Catalin Marian, Alexandra Ioana Moatar |
|---|---|
| Přispěvatelé: | Molecular Pharmacology, Groningen Research Institute for Asthma and COPD (GRIAC) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Male medicine.medical_specialty Levodopa Antiparkinson Agents/therapeutic use Parkinson's disease Disease Biomarkers/metabolism Motor symptoms LevoDopa Antiparkinson Agents Internal medicine medicine Humans MicroRNAs/metabolism Parkinson Disease/drug therapy Microrna array Aged business.industry Dopaminergic digestive oral and skin physiology Levodopa/therapeutic use Levodopa therapy Parkinson Disease Cell Biology Original Articles miR‐19b Middle Aged medicine.disease nervous system diseases MicroRNAs Molecular Medicine Biomarker (medicine) Original Article Female business Biomarkers medicine.drug |
| Zdroj: | Journal of Cellular and Molecular Medicine Journal of cellular and molecular medicine, 25(18), 8715-8724. Wiley |
| ISSN: | 1582-1838 |
| Popis: | Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs. LevoDopa replacement is the gold standard therapy for PD, as it ameliorates the motor symptoms. However, it does not affect the progression of the disease and its long‐term use triggers severe complications. There are no bona fide biomarkers for monitoring the patients’ response to LevoDopa and predicting the efficacy of levodopa treatment. Here, we have combined qPCR microRNA array screening with analysis of validated miRs in naïve versus Levodopa‐treated PD patients. We have identified plasma miR‐19b as a possible biomarker for LevoDopa therapy and validated this result in human differentiated dopaminergic neurons exposed to LevoDopa. In silico analysis suggests that the LevoDopa‐induced miR‐19b regulates ubiquitin‐mediated proteolysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text